Pliant Therapeutics Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Bernard Coulie
Algemeen directeur
US$11.2m
Totale compensatie
| Percentage CEO-salaris | 5.5% |
| Dienstverband CEO | 8.8yrs |
| Eigendom CEO | 1.1% |
| Management gemiddelde ambtstermijn | 8.7yrs |
| Gemiddelde ambtstermijn bestuur | 7.1yrs |
Recente managementupdates
Recent updates
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?
Sep 13
Pliant Therapeutics: Good Data, But Will Need Watching
Sep 11Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?
Jun 07Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Feb 27Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?
Jul 21Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?
Mar 13Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Sep 10Pliant Therapeutics: Wait For A Better Price To Get In
Aug 20Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M
Aug 08Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?
Jul 28Pliant's PLN-74809 gets FDA fast track status for liver disease
Jul 21Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals
Jul 11Pliant: Major Catalyst Expected Beginning Of 2023
Jun 03We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate
Apr 22Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation
Dec 29We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth
Sep 07Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%
May 17Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 13Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans
Mar 22Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$202m |
| Jun 30 2024 | n/a | n/a | -US$185m |
| Mar 31 2024 | n/a | n/a | -US$171m |
| Dec 31 2023 | US$11m | US$610k | -US$161m |
| Sep 30 2023 | n/a | n/a | -US$155m |
| Jun 30 2023 | n/a | n/a | -US$144m |
| Mar 31 2023 | n/a | n/a | -US$133m |
| Dec 31 2022 | US$11m | US$587k | -US$123m |
| Sep 30 2022 | n/a | n/a | -US$113m |
| Jun 30 2022 | n/a | n/a | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$103m |
| Dec 31 2021 | US$5m | US$556k | -US$97m |
| Sep 30 2021 | n/a | n/a | -US$92m |
| Jun 30 2021 | n/a | n/a | -US$81m |
| Mar 31 2021 | n/a | n/a | -US$75m |
| Dec 31 2020 | US$2m | US$499k | -US$42m |
| Sep 30 2020 | n/a | n/a | US$18m |
| Jun 30 2020 | n/a | n/a | US$19m |
| Mar 31 2020 | n/a | n/a | US$20m |
| Dec 31 2019 | US$2m | US$428k | -US$7m |
Compensatie versus markt: De totale vergoeding ($USD 11.17M ) Bernard } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.18M ).
Compensatie versus inkomsten: De vergoeding van Bernard is gestegen terwijl het bedrijf verliesgevend is.
CEO
Bernard Coulie (58 yo)
8.8yrs
Tenure
US$11,165,999
Compensatie
Dr. Bernard Coulie, Ph D, M.D. M.B.A. is Independent Director of Septerna, Inc. from December 2023. He serves as Independent Director at SQZ Biotechnologies Company since July 2021 and serves as its Indepe...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | no data | US$11.17m | 1.1% $ 10.1m | |
| Chief Financial Officer | 5.9yrs | US$4.44m | 0.31% $ 2.9m | |
| General Counsel & Corporate Secretary | 4.1yrs | US$3.32m | 0.060% $ 555.1k | |
| Chief Business Officer | 8.7yrs | US$4.36m | 0.32% $ 2.9m | |
| Chief Medical Officer | 6.5yrs | US$4.69m | 0.22% $ 2.0m | |
| Scientific Founder & Member of Scientific Advisory Board | 9.8yrs | geen gegevens | geen gegevens | |
| Scientific Founder & Member of Scientific Advisory Board | 9.8yrs | geen gegevens | geen gegevens | |
| Scientific Founder & Member of Scientific Advisory Board | 9.8yrs | geen gegevens | geen gegevens | |
| Scientific Founder & Member of Scientific Advisory Board | 9.8yrs | geen gegevens | geen gegevens | |
| Interim Chief Technology Officer | no data | geen gegevens | geen gegevens | |
| Vice President of Investor Relations & Corporate Communications | no data | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | 1.8yrs | geen gegevens | 0.0013% $ 12.1k |
8.7yrs
Gemiddelde duur
51yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van PLRX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 8.8yrs | US$11.17m | 1.1% $ 10.1m | |
| Scientific Founder & Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Scientific Founder & Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Scientific Founder & Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Scientific Founder & Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 4.9yrs | US$278.71k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 8.3yrs | US$277.21k | 0.058% $ 532.9k | |
| Independent Director | 7.3yrs | US$271.96k | 0.048% $ 444.7k | |
| Independent Chairman | 6.9yrs | US$296.71k | 0.16% $ 1.5m | |
| Independent Director | 5.7yrs | US$277.96k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens |
7.1yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PLRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.1 jaar).